{"id":"W2006813505","doi":"10.1097/jto.0b013e3181cee24f","title":"Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Interim analysis; Lung cancer; Febrile neutropenia; Phases of clinical research; Discontinuation; Adverse effect; Leukopenia; Combination therapy; Oncology; Surgery; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006118733,0.0002223376,0.001340234,0.0004515191,0.00006399051,0.000008513489,0.0001484213,0.000130098,0.0005296448],"category_scores_gemma":[0.00003974621,0.0001384559,0.0001542298,0.0003178855,0.00007722731,0.0001446125,0.00003120539,0.0006051508,9.257204e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003564947,"about_ca_system_score_gemma":0.001451412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001823655,"about_ca_topic_score_gemma":0.000984831,"domain_scores_codex":[0.99814,0.000143287,0.0009228269,0.0002101821,0.0003379467,0.0002457158],"domain_scores_gemma":[0.9975639,0.0001817019,0.001166474,0.0002366151,0.0006778568,0.0001734733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8462779,0.02837812,0.0318705,0.00009575804,0.001318504,0.0002189688,0.008987891,0.0003218963,0.00370454,0.000002978836,0.00009102639,0.07873192],"study_design_scores_gemma":[0.9364226,0.04261854,0.01171353,0.0001406809,0.001361053,0.00003343222,0.001418328,0.00009543911,0.005328716,0.00001360533,0.0006966898,0.0001573373],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947646,0.0004905823,0.00005089265,0.0003272527,0.000697673,0.002663407,0.00001245925,0.000006852598,0.0009863172],"genre_scores_gemma":[0.9970263,0.0001199098,0.001755271,0.0001653888,0.0001514356,0.0001261711,0.000009563619,0.00002980757,0.0006162141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09014477,"threshold_uncertainty_score":0.5799239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01931952276441427,"score_gpt":0.4345778015929574,"score_spread":0.4152582788285432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}